Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q4 2024 Earnings Presentation
9 slides from Oncoinvent Asa's earnings presentation, Feb 26, 2025
Slide 1: Selective AXL Inhibition in Serious Diseases
Selective AXL Inhibition in Serious Diseases Q4 2024 presentation
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or forecasts will come to pass or that any forecast result constitute forward-looking statements. Forward-looking will be achieved, and you are cautioned not to place any statements are statements that are not historical fa
Slide 3: Discontinuation of 1L STK11M NSCLC study
Discontinuation of 1L STK11M NSCLC study • BGBC016: Study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). • While encouraging safety and efficacy was seen in Ph1b porti
Slide 4: Study design BGBC016 in 1L STK11m NSCLC
Study design BGBC016 in 1L STK11m NSCLC Ph1b – 3 doses studied Ph1b/2a Overlapping Protocol First dose moved into Ph2a Second dose moved into Ph2a Ph1b (US) Dose Escalation Ph2a (US & EU) Expansion Study Phase 3 doses 2 doses 1L Advanced/Metastatic NS-NSCLC pts 40 1L STK11m NS-NSCLC pts Patient Popu
Slide 5: BGBC016 Ph1b/2a data in 1L STK11m NSCLC pts
BGBC016 Ph1b/2a data in 1L STK11m NSCLC pts Real-World-Data in BGBC016 Results STK11m Pts. Ph1b/2a Skoulidis (Nature Ph1b STK11m Ph 2a STK11m Combined 2024) # patients 3 10 13 119 ORR 1 (33%) 0 (0%) 1 (7.7%) 33% DCR 3 (100%) 3 (30%) 6 (46%) 69.5% ORR: Overall Response Rate (Complete Response + Parti
Slide 6: Strategic opportunities remain for bemcentinib
Strategic opportunities remain for bemcentinib Supportive Bemcentinib Potential Development Potential Indication Market Considerations Dataset Path Hospitalized severe viral • 300-900K patients at 177 COVID pts treated + Several infections risk/year in the US preclinical data against a funded/sponso
Slide 7: Key financials Q4/Year-end 2024
Key financials Q4/Year-end 2024 (NOK million Q4 2024 Q4 2023 FY 2024 FY 2023 Operating revenues 0.7 0.4 0.8 0.4 Operating expenses 34.2 43.9 152.1 192.2 Operating profit (-loss) (33.5) (43.5) (151.2) (191.8) Profit (-loss) after tax (28.6) (41.6) (139.3) (190.4) Average cash use below guidance Basic
Slide 8: Next steps for BerGenBio
Next steps for BerGenBio • Exploring strategic alternatives to maximize shareholder value, including potential merger, acquisition, or other value-enhancing transactions. The company will assess the best path forward in alignment with shareholder interests. • Closing the BGBC016 study as quickly as
Slide 9: BerGenBio
BerGenBio